Pfaudler wins contract to equip Chinese pharmaceutical plant

Published: 18-Jul-2011
Manufacturing

With glass-lined reactor vessels and thermal control units

Pfaudler wins contract to equip Chinese pharmaceutical plant
Pfaudler, a global supplier of glass lined reactors and modular process systems for the pharmaceutical industry, has won a contract to supply 43 glass-lined reactor vessels and nine thermal control units (TCUs) to a new pharmaceutical plant in Southern China. Financial details were not disclosed.

Pfaudler-Balfour, based in Leven, Fife, Scotland has designed the TCU heating and cooling systems (design range of -29/+200°C) in close consultation with Robbins & Myers Process Solutions Group company Suzhou Pfaudler, based in China, which is manufacturing glass-lined reactor vessels (ranging from 50 to 3000L) and building the TCUs.

Pfaudler says its design-build capability and proven track record helped secure this ‘significantly large order’ for process plant equipment.

With manufacturing sites in the UK, Germany, India, China, US, Mexico and Brazil, Pfaudler supplies modular systems that incorporate products and materials from the Robbins & Myers Process Solutions Group, including reactors, condensers, utility systems, columns, evaporators and heat exchangers.

See more

You may also like

Manufacturing
Pfaudler supplies two mobile reactors to UK pharma plant

Pfaudler supplies two mobile reactors to UK pharma plant

Read more
They are being used for processing solvents, acids and alkalis

Trending Articles

  1. Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale
  2. FDA inspection readiness: Preparing for surveillance and pre-approval inspections Preparing pharma and biotech teams for continuous FDA inspection readiness, mock inspections and proactive regulatory risk management
  3. Hovione to install first ConsiGma CDC Flex continuous tableting line in US The CDMO is investing $35m in a next-generation continuous tableting line at its 89 Twin Rivers facility in New Jersey, creating an integrated US pathway from spray-dried amorphous solid dispersions to commercial tablet production
  4. SCHOTT Pharma makes decarbonisation measurable Validated carbon footprint tool supports informed Scope 3 reduction decisions for pharmaceutical packaging
  5. FDA Form 483 explained: responding to findings and managing regulatory risk Explore what a Form FDA 483 means, how to respond within 15 business days, assess patient risk, address observations and understand how FDA evaluates responses and inspection outcomes

You may also like

Manufacturing
Pfaudler supplies two mobile reactors to UK pharma plant

Pfaudler supplies two mobile reactors to UK pharma plant

They are being used for processing solvents, acids and alkalis
Manufacturing
Patented device reinvents Solid Phase Extraction

Patented device reinvents Solid Phase Extraction

Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
Manufacturing
Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility

Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility

The €29m ATLab site will target up to 10,000 doses annually and its two-hour proximity to major European airports meets the critical 24-hour production-to-administration window imposed by lead-212's 10.6-hour half-life
Manufacturing
Lonza advances aseptic spray drying for high-dose biologics

Lonza advances aseptic spray drying for high-dose biologics

This new technology platform addresses stability, concentration, and delivery challenges in biologics, including new modalities
Manufacturing
Catalent launches ten-month gene-to-drug substance programme for complex biologics

Catalent launches ten-month gene-to-drug substance programme for complex biologics

The accelerated pathway extends the CDMO's Rapid Antibody framework to bispecifics and next-generation formats — targeting master cell bank release by month seven and bulk drug substance lot release by month ten
Design & Build
Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite

Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite

The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale
Manufacturing
Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma Ltd. (“PPL”) (NSE: PPLPHARMA | BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October
Subscribe now